
ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL
Two Onc Docs
00:00
Efficacy results: progression‑free survival
Kareen reports the primary endpoint: 24‑month PFS 93.4% with pirtobrutinib versus 70.7% with BR.
Play episode from 06:14
Transcript


